Unoprostone (INN) is a prostaglandin analogue. Its isopropyl ester, unoprostone isopropyl, was marketed under the trade name Rescula for the management of open-angle glaucoma and ocular hypertension.[1][2]

It was approved by the Food and Drug Administration in 2000.[3]

In 2009, Sucampo Pharmaceuticals acquired the rights to the drug in the U.S. and Canada.[4]

In 2015, the drug was discontinued in the U.S.[citation needed]

References

  1. ^ Micromedex Detailed Consumer Information
  2. ^ Fung DS, Whitson JT (2014). "An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy". Clinical Ophthalmology. 8. Auckland, N.Z.: 543–54. doi:10.2147/OPTH.S41562. PMC 3958522. PMID 24648719.
  3. ^ "Drug Approval Package". Food and Drug Administration.
  4. ^ "Sucampo Pharmaceuticals, Inc. Acquires Rights to Rescula for U.S. and Canada" (Press release). Business Wire. April 24, 2009.